Ipamorelin 10MG

Ipamorelin – Research Overview
Chemical name: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Class: Selective growth hormone secretagogue (GHS)
Primary target: Ghrelin / Growth Hormone Secretagogue Receptor (GHSR-1a)
Molecular weight: ~711.9 Da
Activity: Mimics the action of ghrelin on pituitary growth hormone release (signals GH secretion without affecting other hormones)

Ipamorelin is a synthetic pentapeptide investigated in preclinical research for its highly selective ability to stimulate growth hormone release (GH secretion) through the ghrelin receptor.

It is known for its selectivity, meaning it does not significantly alter cortisol, prolactin, or ACTH in research models
(unlike some older GHS peptides).

Molecular & Pharmacological Profile
In preclinical models, Ipamorelin has been shown to:

• Activate GHSR-1a receptors (growth hormone secretagogue receptor)
• Increase pulsatile GH release (natural GH spikes)
• Avoid significant activation of other pituitary hormones
• Display high specificity to ghrelin pathways (minimal off-target effects)
• Produce dose-dependent GH secretion in animal models
  These characteristics make Ipamorelin a widely used peptide in endocrine and metabolic research.

Mechanism of Action (Preclinical)
Ipamorelin acts through the ghrelin receptor, producing GH release in a controlled and predictable way.

1. Binding to GHSR-1a (ghrelin receptor)
   (the receptor ghrelin uses to stimulate GH secretion)
2. Triggering GH release from the anterior pituitary
   (increases natural GH pulses in preclinical models)
3. Lower effect on ACTH and cortisol pathways
   (reduced side-hormone stimulation compared to GHRP-6 or Hexarelin)
4. Mimicking natural GH rhythms
   (GH rises in pulses rather than a constant elevation)
5. Minimal impact on appetite signaling
   (preclinical studies show weaker hunger stimulation than true ghrelin)

Preclinical Research: Potential Applications
Ipamorelin has been investigated across various animal and cell-based research contexts:

1. Growth Hormone & Endocrine Research
   Study of GH release mechanisms
   Investigation into GHSR-1a pathway signaling
   Analysis of pulsatile GH vs. continuous GH patterns
2. Metabolic Research
   Interactions between GH and fat metabolism
   GH-induced effects on energy expenditure
   Observing GH’s impact on body composition models
   (GH affects fat and lean-mass pathways in animals)
3. Bone & Connective Tissue Research
   GH-stimulated IGF-1 expression in tissues (downstream GH effects)
   Preclinical studies on bone remodeling markers
   Exploring GH’s role in collagen synthesis
4. Neurological & Cognitive Models
   GH pathways have been connected to:
   Neural plasticity
   Cognitive performance
   Neuroprotection mechanisms
   (these findings apply to GH pathways, not directly to human outcomes)
5. Anti-inflammatory & Recovery Pathways (Preclinical)

GH upregulates:

• Repair-associated genes
• Anti-inflammatory pathways
• Cellular regeneration markers
• Ipamorelin is often studied alongside CJC-1295 for combined GH modulation, but this overview focuses on Ipamorelin alone.
• Efficacy Observed in Preclinical Models
• Growth Hormone Release
• Strong, dose-dependent GH pulse increases
• Less desensitization vs. older GHRPs
• Minimal stimulation of non-GH pituitary hormones
  (very low prolactin and ACTH activation)

Metabolic Findings
Rodent studies show:

• Increased lipolysis (breaking down stored fat)
• Increased fatty-acid oxidation (burning fat for energy)
• Improved metabolic efficiency in GH-regulated pathways

Bone and Tissue Studies
GH-related findings include:

• Increased collagen synthesis
• Enhanced osteoblast activity (bone-building cells)
• Upregulation of IGF-1 in certain tissues

Neurological Findings
GH modulates:

• Neuronal survival pathways
• Synaptic plasticity markers

Learning and memory biomarkers
(Ipamorelin’s effects here are indirect through GH pathways.)

Key areas of study and potential use include:
Growth Hormone Deficiency (GHD) treatment: As it stimulates GH release, it has been investigated as a potential treatment for both adult and childhood GHD.

Body Composition Improvement: Studies show potential for increasing lean muscle mass and reducing body fat, making it a focus in age management and fitness contexts.
Bone Health: Research, primarily in animal models, has indicated that ipamorelin may increase bone mineral density and enhance bone formation, suggesting potential in the prevention and treatment of osteoporosis.
Wound and Injury Healing: By promoting cellular repair and collagen production, it is being investigated for enhancing recovery from injuries, exercise, or surgery.
Sleep Quality: Clinical and preclinical evidence suggests ipamorelin can improve sleep architecture, specifically enhancing slow-wave sleep duration and overall sleep quality.

Metabolic Syndrome and Type 2 Diabetes Management: It is being investigated for its potential to improve insulin sensitivity and lipid profiles.

Anti-Aging and Regenerative Medicine: Due to the natural decline of GH with age, ipamorelin is used in age management protocols to help mitigate related symptoms like fatigue, decreased muscle tone, and reduced skin elasticity.

Neuroprotection and Cognitive Function: Emerging studies suggest potential benefits for cognitive function, including memory and focus, and neuroprotective effects.

HIV-associated Wasting: Ipamorelin has been an investigational use for managing muscle atrophy associated with conditions like HIV.

Safety & Tolerability (Preclinical)
Ipamorelin is considered one of the most selective GH secretagogues in preclinical research:

• Low off-target hormone activation
  (minimal cortisol, prolactin, and ACTH changes)

• Well-tolerated in rodent studies at standard research doses

• Low desensitization rate
  (receptor continues responding to stimulation)

• No significant effect on hunger
  (unlike ghrelin mimetics such as GHRP-6)

• Long-term human safety remains undetermined, and Ipamorelin is not approved for therapeutic use.

Regulatory Status & Disclaimer

• Ipamorelin is an investigational research peptide.
• It is not approved by the FDA or any regulatory body for medical, dietary, cosmetic, or therapeutic use.
• For Research Use Only.
• Not for human consumption.
• Not for veterinary use.
• Not for diagnostic or therapeutic purposes.
• No medical claims are made or implied.

Key References (Preclinical)
Raun K. et al. Ipamorelin: Selective GH secretagogue profile in rats. Endocrinology.
Svensson J. et al. GHSR-1a pathway activation by Ipamorelin. Growth Horm IGF Res.
Broglio F. et al. Comparison of Ipamorelin with GHRP-6 in endocrine models. J Clin Endocrinol Metab.
Kojima et al. Ghrelin receptor signaling pathways and GH release. Nature.
Hickey G. GH secretagogues and metabolic modulation in animal models. Peptides.

Product Note:

All products are shipped in lyphollized or powder form and must be reconstituted to a liquid for research and testing. We are unable to provide any dosing instructions, however all products should be considered pharmaceutical grade.

Storage: Peptides should be stored in a dry, cool, dark place. For best preservation, store at 4°C or colder away from bright light.